Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04927572 · ClinicalTrials.gov registry record · Phase 1
Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis
A Phase 1 study, sponsored by Vyne Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT04927572 is a Phase 1 study that has completed, run by Vyne Therapeutics. The registered enrollment target is 21 participants.
The verdict
NCT04927572, a Phase 1 study, has completed, sponsored by Vyne Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
A Phase I/IIa Randomized, Double-Blind, Vehicle-Controlled Clinical Trial with Separate Open-Label Active Treatment Phase Evaluating the Safety, Pharmacokinetics and Efficacy of FMX114 Gel in the Treatment of Mild-to-Moderate Atopic Dermatitis in Adults
Interventions
- OTHER Vehicle
- DRUG FMX114
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-10-13 |
| Est. Completion | 2022-08-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04927572
The ClinicalTrials.gov registry entry for NCT04927572 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vyne Therapeutics, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT04927572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04927572 about?
NCT04927572 is a clinical study titled "Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis". A Phase I/IIa Randomized, Double-Blind, Vehicle-Controlled Clinical Trial with Separate Open-Label Active Treatment Phase Evaluating the Safety, Pharmacokinetics and Efficacy of FMX114 Gel in the Treatment of Mild-to-Moderate Atopic Dermatitis in Adults
What is the current status of trial NCT04927572?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2021-10-13. Estimated completion is 2022-08-09.
What interventions are being tested in trial NCT04927572?
The interventions under investigation include: Vehicle (OTHER), FMX114 (DRUG).
Who is sponsoring clinical trial NCT04927572?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.